Table 1 Summary of the 23 CVOTs included
Trial/year of publication | Study drug/mean follow up (years) | Participants (n) | Age mean/median age (years) | Male sex (n, %) | Participants with prior CV disease (%) | Primary outcome | Study funder |
|---|---|---|---|---|---|---|---|
DPP-4 inhibitors | |||||||
 SAVOR-TIMI53/2013 | Saxagliptin/2.1 | 16,492 | 65 | 11,050 (67%) | 78 | MACE | AstraZeneca |
 EXAMINE/2013 | Alogliptin/1.5 | 5380 | 61 | 3658 (68%) | 100 | MACE | Takeda |
 TECOS/2015 | Sitagliptin/3.0 | 14,523 | 65 | 10,311 (71%) | 100 | MACE | Merck |
 CARMELINA/2019 | Linagliptin/2.2 | 6979 | 66 | 4788 (68.6%) | 57 | MACE | Boehringer/Lilly |
GLP-1RA | |||||||
 ELIXA, 2015 | Lixisenatide/2.1 | 6068 | 60.3 | 3174 (69.3%) | 100 | MACE | Sanofi |
 LEADER/2016 | Liraglutide/3.8 | 9340 | 64.3 | 6003 (64.3%) | 81 | MACE | NovoNordisk |
 SUSTAIN-6/2016 | Semaglutide/2.1 | 3297 | 64.6 | 2002 (60.7%) | 83 | MACE | NovoNordisk |
 EXSCEL/2017 | Exenatide/3.2 | 14,752 | 62 | 9149 (62%) | 73.1 | MACE | Amylin |
 HARMONY/2018 | Albiglutide/1.6 | 9463 | 64.1 | 6569 (69.4%) | 100 | MACE | GlaxoSmithKline |
 REWIND/2019 | Dulaglutide/5.4 | 9901 | 66.2 | 5312 (53.7%) | 31.4 | MACE | Boehringer/Lilly |
 PIONEER 6 /2019 | Semaglutide/1.3 | 3183 | 66.0 | 2176 (68.4%) | 84.7 | MACE | NovoNordisk |
 AMPLITUDE-O/2021 | Epfeglenatide/1.8 | 4076 | 64.5 | 2732 (67%) | 89.6 | MACE | SANOFI |
SGLT-2 inhibitors | |||||||
 EMPA-REG/2015 | Empagliflozin/3.1 | 7020 | 63.2 | 5016 (71.5%) | 99 | MACE | Boehringer/Lilly |
 CANVAS/2017 | Canagliflozin/2.4 | 10,142 | 63.2 | 6509 (64.2%) | 66 | MACE | Janssen |
 DECLARE/2019 | Dapagliflozin/4.2 | 17,16 | 63.8 | 10,738 (62.6%) | 40.6 | MACE | AstraZeneca |
 CREDENCE/2019 | Canagliflozin/2.6 | 4401 | 63 | 2907 (66.1%) | 50.4 | Composite renal | Janssen |
 DAPA-HF/2019 | Dapagliflozin/1.5 | 4744 | 66 | 3131 (66%) | 100 | HHF or CV death | AstraZeneca |
 VERTIS-CV/2020 | Ertugliflozin/3.5 | 8246 | 64.4 | 5769 (70%) | 100 | MACE | Merck |
 DAPA-CKD/2020 | Dapagliflozin/2.4 | 4304 | 61.8 | 2879 (66.9%) | 38 | Composite renal | AstraZeneca |
 EMPEROR-R/2020 | Empagliflozin/1.3 | 3730 | 66.8 | 2837 (76%) | 100 | HHF or CV death | Boehringer/Lilly |
 SCORED/2021 | Sotagliflozin/1.3 | 10,584 | 69 | 5896 (55.7%) | NA | HHF or CV death | Sanofi/Lexicon |
 SOLOIST-WHF/2021 | Sotagliflozin/0.75 | 1222 | 70 | 810 (63.3%) | 100 | HHF or CV death | Sanofi/Lexicon |
 EMPEROR-P/2021 | Empagliflozin/2.2 | 5988 | 71.9 | 3317 (55.4%) | 100 | HHF or CV death | Boehringer/Lilly |